Owlet, Inc. (NYSE: OWLT)

Sector: Healthcare Industry: Medical Devices CIK: 0001816708
Market Cap 159.28 Mn
P/B -2.94
P/E -3.75
P/S 1.60
ROIC (Qtr) 31.73
Div Yield % 0.00
Rev 1y % (Qtr) 44.60
Total Debt (Qtr) 24.95 Mn
Debt/Equity (Qtr) -0.46
Add ratio to table...

About

Owlet, Inc., a company that trades under the ticker symbol OWLT, operates in the digital parenting solutions industry. The company is dedicated to providing innovative digital solutions that empower parents with real-time data and insights to help them care for their children. Through its range of products, Owlet aims to give parents peace of mind and confidence in their parenting abilities. In its main business activities, Owlet specializes in the development of digital parenting solutions. These solutions are designed to monitor a baby's sleep,...

Read more

Investment thesis

Bull case

  • Strong tangible asset base of 73.65M provides 2.95x coverage of total debt 24.95M, indicating robust asset backing and low credit risk.
  • Tangible assets of 73.65M provide exceptional 34.74x coverage of deferred revenue 2.12M, showing strong service capability backing.
  • Retained earnings of (298.68M) represent substantial 5.52x of equity (54.14M), indicating strong internal capital generation.
  • Robust tangible asset base of 73.65M provides 8.47x coverage of working capital 8.70M, indicating strong operational backing.
  • R&D investment of 12.98M represents healthy 6.12x of deferred revenue 2.12M, indicating strong future innovation pipeline.

Bear case

  • Investment activities of (493000) provide weak support for R&D spending of 12.98M, which is -0.04x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (7.02M) provides insufficient coverage of deferred revenue obligations of 2.12M, which is -3.31x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (7.02M) shows concerning coverage of stock compensation expenses of 6.10M, with a -1.15 ratio indicating potential earnings quality issues.
  • Free cash flow of (7.59M) provides weak coverage of capital expenditures of 572000, with a -13.27 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (35.25M) show weak coverage of depreciation charges of 606000, with a -58.16 ratio indicating high capital intensity and potential reinvestment needs.

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.11 2.13
EV to Cash from Ops. EV/CFO -22.47 2.75
EV to Debt EV to Debt 6.32 17.25
EV to EBIT EV/EBIT -4.47 2.89
EV to EBITDA EV/EBITDA -15.50 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -20.77 29.36
EV to Market Cap EV to Market Cap 0.99 25.09
EV to Revenue EV/Rev 1.58 32.80
Price to Book Value [P/B] P/B -2.94 4.73
Price to Earnings [P/E] P/E -3.75 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) -14.61 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -8.38 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -14.63 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 10.36 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -254.56 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 28.36 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) -254.70 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) -279.99 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) -65.90 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 53.40 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 35.72 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 1.33 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.38 1.80
Current Ratio Curr Ratio (Qtr) 1.14 4.18
Debt to Equity Ratio Debt/Equity (Qtr) -0.46 1.20
Interest Cover Ratio Int Coverage (Qtr) -8.38 196.93
Times Interest Earned Times Interest Earned (Qtr) -8.38 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -34.80 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -35.37 -2,478.60
EBT Margin % EBT Margin % (Qtr) -39.60 -2,690.42
Gross Margin % Gross Margin % (Qtr) 52.10 30.80
Net Profit Margin % Net Margin % (Qtr) -42.60 -2,821.53